STEMPOINT CAPITAL LP
Long book
$1.03B
Q1 2026
Positions
70
Top-10 weight
46%
concentration
Last quarter
+25.9%
SPY +14.8%
Turnover
64%
of book per quarter
Strategy in plain words
auto-generated from filingsSTEMPOINT CAPITAL LP is a concentrated fundamental stock-picker, specialised in healthcare (97% of the long book), running a $1.03B US long book across 70 positions.
The portfolio is moderately concentrated (top 10 ≈ 46% of the book). Turnover is high — positions rotate quickly, so individual names matter less than the process. Current anchor positions: SCHOLAR ROCK HOLDING CORP, ABIVAX SA-ADR, SYNDAX PHARMACEUTICALS INC, REVOLUTION MEDICINES INC, IMMUNOVANT INC.
Over the last 9 quarters its long book ran on average 1.9pp per quarter ahead of the S&P 500, beating the index in 4 of 9 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-12.1%
Q2 2024
+2.3%
Q3 2024
-8.8%
Q4 2024
-18.8%
Q1 2025
-1.6%
Q2 2025
+44.6%
Q3 2025
+23.7%
Q4 2025
+2.1%
Q1 2026
+25.9%
Sector allocation
Healthcare 96%
Materials 3%
Financials 1%
Long book by quarter
What does STEMPOINT CAPITAL own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| SRRK SCHOLAR ROCK HOLDING CORP | Healthcare | 2.1M | $101.8M | 9.9% | +133.5% |
| SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 2.4M | $56.8M | 5.5% | +81.5% |
| RVMD REVOLUTION MEDICINES INC | Healthcare | 563.3K | $54.8M | 5.3% | +808.0% |
| IMVT IMMUNOVANT INC | Healthcare | 1.5M | $37.1M | 3.6% | +131.5% |
| PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 112.5K | $36.3M | 3.5% | +434.2% |
| MBX MBX BIOSCIENCES INC | Healthcare | 998.9K | $29.8M | 2.9% | +1171.7% |
| MLYS MINERALYS THERAPEUTICS INC | Healthcare | 1.1M | $28.9M | 2.8% | +267.8% |
| ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 726.9K | $28.5M | 2.8% | New |
| CGON CG ONCOLOGY INC | Healthcare | 411.2K | $27.8M | 2.7% | New |
| BHVN BIOHAVEN LTD | Healthcare | 3.2M | $27.0M | 2.6% | New |
| ROIV ROIVANT SCIENCES LTD | Healthcare | 771.6K | $21.4M | 2.1% | -20.2% |
| EYPT EYEPOINT INC | Healthcare | 1.6M | $20.9M | 2.0% | +358.3% |
| ARQT ARCUTIS BIOTHERAPEUTICS INC | Healthcare | 827.6K | $19.5M | 1.9% | +268.2% |
| SRZN SURROZEN INC | Healthcare | 721.6K | $19.2M | 1.9% | +16.4% |
| AMLX AMYLYX PHARMACEUTICALS INC | Healthcare | 1.3M | $18.6M | 1.8% | +137.0% |
| DYN DYNE THERAPEUTICS INC | Healthcare | 1.0M | $18.4M | 1.8% | +21.2% |
| EWTX EDGEWISE THERAPEUTICS INC | Healthcare | 581.7K | $18.3M | 1.8% | +61.2% |
| CYTK CYTOKINETICS INC | Healthcare | 259.2K | $17.1M | 1.7% | +76.3% |
| SYRE SPYRE THERAPEUTICS INC | Healthcare | 335.2K | $16.9M | 1.6% | +935.3% |
| DNLI DENALI THERAPEUTICS INC | Healthcare | 853.1K | $16.4M | 1.6% | +103.6% |
| XENE XENON PHARMACEUTICALS INC | Healthcare | 281.5K | $16.4M | 1.6% | -19.2% |
| CLDX CELLDEX THERAPEUTICS INC | Materials | 508.5K | $16.1M | 1.6% | New |
| PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 145.2K | $15.3M | 1.5% | +144.2% |
| TYRA TYRA BIOSCIENCES INC | Healthcare | 386.4K | $14.8M | 1.4% | New |
| DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 171.0K | $14.4M | 1.4% | +115.7% |
| CELC CELCUITY INC | Healthcare | 120.1K | $13.7M | 1.3% | +1.5% |
| DFTX DEFINIUM THERAPEUTICS INC | Materials | 651.0K | $12.3M | 1.2% | New |
| BIOA BIOAGE LABS INC | Healthcare | 677.3K | $11.8M | 1.1% | New |
| NAMS NEWAMSTERDAM PHARMA CO NV | Healthcare | 361.3K | $11.6M | 1.1% | +394.2% |
| ACAD ACADIA PHARMACEUTICALS INC | Healthcare | 485.1K | $10.8M | 1.0% | New |
| ASMB ASSEMBLY BIOSCIENCES INC | Healthcare | 370.9K | $10.3M | 1.0% | +136.6% |
| ALMS ALUMIS INC | Healthcare | 459.1K | $10.1M | 1.0% | New |
| NRIX NURIX THERAPEUTICS INC | Healthcare | 630.5K | $9.8M | 0.9% | New |
| ZURA ZURA BIO LTD | Healthcare | 1.5M | $9.0M | 0.9% | New |
| EVMN EVOMMUNE INC | Healthcare | 387.6K | $8.8M | 0.8% | +468.3% |
| TNGX TANGO THERAPEUTICS INC | Healthcare | 401.8K | $8.4M | 0.8% | New |
| FTH FAETH THERAPEUTICS INC | Healthcare | 265.7K | $8.4M | 0.8% | New |
| RLMD RELMADA THERAPEUTICS INC | Healthcare | 1.2M | $8.3M | 0.8% | New |
| ERAS ERASCA INC | Healthcare | 479.7K | $7.8M | 0.8% | New |
| JNJ JOHNSON & JOHNSON | Healthcare | 30.8K | $7.5M | 0.7% | -11.9% |
| XFOR X4 PHARMACEUTICALS INC | Healthcare | 1.7M | $7.0M | 0.7% | +89.4% |
| PCVX VAXCYTE INC | Healthcare | 118.1K | $6.9M | 0.7% | New |
| WHWK WHITEHAWK THERAPEUTICS INC | Healthcare | 1.9M | $6.5M | 0.6% | +28.8% |
| HLXC HELIX ACQUISITION CORP-CL A | Financials | 610.1K | $6.2M | 0.6% | New |
| TENX TENAX THERAPEUTICS INC | Healthcare | 377.4K | $6.0M | 0.6% | New |
| ALKS ALKERMES PLC | Healthcare | 161.0K | $5.7M | 0.6% | New |
| PHVS PHARVARIS NV | Healthcare | 173.3K | $4.9M | 0.5% | +196.8% |
| IVVD INVIVYD INC | Healthcare | 3.7M | $4.9M | 0.5% | +278.8% |
| JBIO JADE BIOSCIENCES INC | Healthcare | 308.1K | $4.3M | 0.4% | New |
| TWST TWIST BIOSCIENCE CORP | Healthcare | 86.2K | $4.1M | 0.4% | -83.4% |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR/ANEW HOLDINGS | May 18, 2026 | 84 | $522.3M | canonical | SEC ↗ |
| Q1 2026 | 13F-HR | May 15, 2026 | 83 | $514.6M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 17, 2026 | 78 | $583.2M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 90 | $499.1M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 54 | $311.6M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 62 | $313.7M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 58 | $400.6M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 13, 2024 | 58 | $334.0M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 13, 2024 | 44 | $340.3M | SEC ↗ | |
| Q2 2024 | 13F-HR/ARESTATEMENT | Aug 13, 2024 | 44 | $340.3M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR/ARESTATEMENT | Aug 9, 2024 | 63 | $378.3M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 14, 2024 | 63 | $378.3M | SEC ↗ |